Canagliflozin - CAS# 842133-18-0 Compound 1 McDonnell DP

McDonnell DP

Acebutolol HCl is a cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors

and initial results have shown it to be well tolerated and reasonably effective

is an anti-convulsive medication

suggestive of secondary transcriptional effects and transcription of BRD4 and BRD3 are unaffected

Canagliflozin - CAS# 842133-18-0 Compound 1 McDonnell DPCanagliflozin (INN, trade name Invokana) is a drug for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson. Canagliflozin is an inhibitor of subtype 2 sodium glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the